Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAISE II: Ganaxolone in Refractory Status Epilepticus
NCT05814523Phase 3Withdrawn
- Sponsor
- Marinus Pharmaceuticals
- Start
- Mar 2024
- Primary completion
- Aug 2024
- Modality
- Allosteric Modulators
- Countries
- 16
01
Overview
A Phase 3 trial of ganaxolone in status epilepticus (SE), sponsored by Marinus Pharmaceuticals. Planned start Mar 2024; status: withdrawn.
02
Drugs
ganaxolone
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on NCT05814523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05814523.